News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
863,924 Results
Type
Article (87579)
Company Profile (823)
Press Release (775502)
Multimedia
Podcasts (180)
Webinars (28)
Section
Business (233119)
Career Advice (4140)
Deals (39818)
Drug Delivery (141)
Drug Development (91300)
Employer Resources (203)
FDA (18304)
Job Trends (17407)
News (397534)
Policy (39933)
Tag
Academia (3005)
Academic (2)
Accelerated approval (19)
Adcomms (35)
Allergies (134)
Alliances (56980)
ALS (149)
Alzheimer's disease (1696)
Antibody-drug conjugate (ADC) (273)
Approvals (18347)
Artificial intelligence (528)
Autoimmune disease (111)
Automation (30)
Bankruptcy (406)
Best Places to Work (12634)
BIOSECURE Act (23)
Biosimilars (169)
Biotechnology (487)
Bladder cancer (141)
Brain cancer (54)
Breast cancer (535)
Cancer (4263)
Cardiovascular disease (381)
Career advice (3562)
Career pathing (38)
CAR-T (260)
CDC (57)
Cell therapy (721)
Cervical cancer (33)
Clinical research (75996)
Collaboration (1471)
Company closure (4)
Compensation (986)
Complete response letters (64)
COVID-19 (2966)
CRISPR (88)
C-suite (642)
Cystic fibrosis (143)
Data (5170)
Decentralized trials (2)
Denatured (65)
Depression (118)
Diabetes (472)
Diagnostics (7121)
Digital health (39)
Diversity (12)
Diversity, equity & inclusion (49)
Drug discovery (251)
Drug pricing (197)
Drug shortages (36)
Duchenne muscular dystrophy (210)
Earnings (99564)
Editorial (56)
Employer branding (25)
Employer resources (172)
Events (133776)
Executive appointments (1002)
FDA (20928)
Fibrodysplasia Ossificans Progressiva (4)
Friedreich's ataxia (6)
Frontotemporal dementia (19)
Funding (1320)
Gene editing (187)
Generative AI (52)
Gene therapy (579)
GLP-1 (1050)
Government (5399)
Grass and pollen (8)
Guidances (375)
Healthcare (20940)
HIV (49)
Huntington's disease (41)
IgA nephropathy (75)
Immunology and inflammation (267)
Immuno-oncology (22)
Indications (61)
Infectious disease (3221)
Inflammatory bowel disease (193)
Inflation Reduction Act (16)
Influenza (104)
Intellectual property (202)
Interviews (816)
IPO (17934)
IRA (59)
Job creations (5197)
Job search strategy (2866)
Kidney cancer (17)
Labor market (82)
Layoffs (645)
Leadership (37)
Legal (10152)
Liver cancer (93)
Longevity (13)
Lung cancer (604)
Lymphoma (292)
Machine learning (33)
Management (66)
Manufacturing (680)
MASH (157)
Medical device (14922)
Medtech (14952)
Mergers & acquisitions (22808)
Metabolic disorders (1229)
Multiple sclerosis (143)
NASH (23)
Neurodegenerative disease (242)
Neuropsychiatric disorders (66)
Neuroscience (2792)
NextGen: Class of 2025 (7703)
Non-profit (5098)
Now hiring (60)
Obesity (591)
Opinion (317)
Ovarian cancer (148)
Pain (173)
Pancreatic cancer (183)
Parkinson's disease (248)
Partnered (32)
Patents (436)
Patient recruitment (347)
Peanut (58)
People (66404)
Pharmaceutical (145)
Pharmacy benefit managers (29)
Phase I (23440)
Phase II (32979)
Phase III (24867)
Pipeline (3118)
Policy (308)
Postmarket research (3554)
Preclinical (10598)
Press Release (72)
Prostate cancer (208)
Psychedelics (52)
Radiopharmaceuticals (283)
Rare diseases (720)
Real estate (7424)
Recruiting (79)
Regulatory (28188)
Reports (65)
Research institute (2700)
Resumes & cover letters (651)
Rett syndrome (18)
RNA editing (15)
RSV (78)
Schizophrenia (140)
Series A (217)
Series B (163)
Service/supplier (30)
Sickle cell disease (85)
Special edition (26)
Spinal muscular atrophy (170)
Sponsored (42)
Startups (4321)
State (2)
Stomach cancer (17)
Supply chain (103)
Tariffs (96)
The Weekly (113)
Vaccines (1071)
Venture capital (69)
Weight loss (414)
Women's health (65)
Worklife (21)
Date
Today (113)
Last 7 days (973)
Last 30 days (3746)
Last 365 days (33656)
2025 (29460)
2024 (38142)
2023 (42568)
2022 (53929)
2021 (58724)
2020 (57666)
2019 (51338)
2018 (39124)
2017 (37190)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1285)
Alabama (81)
Alaska (7)
Arizona (312)
Arkansas (14)
Asia (51115)
Australia (8986)
California (10181)
Canada (2980)
China (970)
Colorado (426)
Connecticut (453)
Delaware (291)
Europe (117526)
Florida (1485)
Georgia (331)
Hawaii (3)
Idaho (68)
Illinois (837)
India (57)
Indiana (495)
Iowa (20)
Japan (341)
Kansas (128)
Kentucky (39)
Louisiana (27)
Maine (80)
Maryland (1344)
Massachusetts (7589)
Michigan (324)
Minnesota (597)
Mississippi (4)
Missouri (128)
Montana (33)
Nebraska (26)
Nevada (110)
New Hampshire (81)
New Jersey (2803)
New Mexico (32)
New York (2711)
North Carolina (1467)
North Dakota (10)
Northern California (4727)
Ohio (314)
Oklahoma (22)
Oregon (51)
Pennsylvania (2088)
Puerto Rico (20)
Rhode Island (46)
South America (1655)
South Carolina (52)
South Dakota (1)
Southern California (3885)
Tennessee (156)
Texas (1580)
United States (37184)
Utah (305)
Virginia (259)
Washington D.C. (85)
Washington State (858)
West Virginia (4)
Wisconsin (106)
Wyoming (2)
There are 863,924 results that match your search.
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Funding
Biohaven Seeks $150 Million From Wall Street Following FDA Rejection
After the FDA rejected its spinocerebellar ataxia treatment, Biohaven missed out on a $150 million payment from Oberland Capital. Now the company is reshuffling its pipeline to stay alive.
November 12, 2025
·
3 min read
·
Dan Samorodnitsky
Stylus Medecine
Stylus Medicine is developing in vivo genetic medicines to unlock cures.
Drug Development
Five Trends That Got Everyone Talking in Pharma and Biotech This Year
In 2025, landmark obesity drug deals, China’s biotech surge, and AI’s deeper integration into pharma operations drove a year of transformation and renewed momentum for life sciences.
November 12, 2025
·
5 min read
·
Jennifer Smith-Parker
Haya Therapeutics
HAYA Therapeutics is a precision medicines company developing RNA-guided programmable therapeutics targeting the regulatory genome for serious health conditions including cardiovascular disease and cancer.
Press Releases
Antiemetics Drugs Market Size Worth USD 30.63 Billion by 2034
November 12, 2025
·
1 min read
Press Releases
Izotropic Launches Podcast Episode #2: AI and the Future of Breast Imaging: How Izotropic is Leading the Innovation
November 12, 2025
·
4 min read
Press Releases
BioMark Aligns with National Strategy to Slash Lung Cancer Mortality with Next-Gen Liquid Biopsy
Next-generation metabolomics and AI technology supports the 2026 - 2035 Pan-Canadian Lung Cancer Action Plan’s call to expand equitable access to life-saving early diagnosis
November 12, 2025
·
3 min read
Press Releases
BioHarvest Sciences to Attend the Craig-Hallum 16th Annual Alpha Select Conference on November 18, 2025
November 12, 2025
·
3 min read
Press Releases
Evia Bio® Introduces CellShieldTM MSC DMSO-Free Cryopreservation Media Kit
November 12, 2025
·
1 min read
Press Releases
L7 Informatics Draws Parallels Between Cloud, Mobile, and AI: Infrastructure Must Come First
November 12, 2025
·
1 min read
1 of 86,393
Next
